Statins lack cost effectiveness in low-risk populations

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.626, 2011-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Conservative approaches cost effective in low-risk bladder cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 663, 2012-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

High-dose eptifibatide cost saving in low-risk PCI patients?

Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Losartan vs atenolol in low-risk patients with hypertension

Inpharma, Vol. 1, Iss. 1509, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia

By Mauskopf J.A.

PharmacoEconomics, Vol. 17, Iss. 6, 2000-06 ,pp. : 611-620

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Withdrawal of Fall-Risk-Increasing Drugs in Geriatric Outpatients

By Nathalie van der Velde Willen Jan Meerding

Drugs & Aging, Vol. 25, Iss. 6, 2008-01 ,pp. : 521-529

Adis International

Access to resources Recommend Favorite